Terms: = Liver cancer AND LEF1, TCF1ALPHA, 51176, ENSG00000138795, Q9UJU2, DKFZp586H0919 AND Prognosis
9 results:
1. Targeting lef1-mediated epithelial-mesenchymal transition reverses lenvatinib resistance in hepatocellular carcinoma.
Li X; Su H; Tang W; Shu S; Zhao L; Sun J; Fan H
Invest New Drugs; 2024 Apr; 42(2):185-195. PubMed ID: 38372948
[TBL] [Abstract] [Full Text] [Related]
2. Exploring risk factors and molecular targets in leukemia patients with COVID-19: a bioinformatics analysis of differential gene expression.
Ullah MA; Moin AT; Nipa JF; Islam NN; Johora FT; Chowdhury RH; Islam S
J Leukoc Biol; 2024 Mar; 115(4):723-737. PubMed ID: 38323674
[TBL] [Abstract] [Full Text] [Related]
3. Synthetic miR-26a mimics delivered by tumor exosomes repress hepatocellular carcinoma through downregulating lymphoid enhancer factor 1.
Hu J; Liu WF; Zhang XY; Shi GM; Yang XR; Zhou KQ; Hu B; Chen FY; Zhou C; Lau WY; Fan J; Wang Z; Zhou J
Hepatol Int; 2023 Oct; 17(5):1265-1278. PubMed ID: 37115456
[TBL] [Abstract] [Full Text] [Related]
4. The Prognostic and Drug-targeting Value of Lymphoid Enhancer-binding Factor-1 in Hepatocellular Carcinoma.
Guo R; Dai H; Liu F; Liu M; Li X; Li T; Liao J; Chen ZS; Liu Y; Fang S
Recent Pat Anticancer Drug Discov; 2022; 18(2):211-223. PubMed ID: 36045537
[TBL] [Abstract] [Full Text] [Related]
5. A linkage between effectual genes in progression of CRC through canonical and non-canonical TGF-β signaling pathways.
Shirin M; Madadi S; Peyravian N; Pezeshkian Z; Rejali L; Hosseini M; Moradi A; Khanabadi B; Sherkat G; Aghdaei HA; Nazemalhosseini-Mojarad E
Med Oncol; 2022 Jan; 39(4):40. PubMed ID: 35092502
[TBL] [Abstract] [Full Text] [Related]
6. Nucleoporin 93 mediates β-catenin nuclear import to promote hepatocellular carcinoma progression and metastasis.
Lin CS; Liang Y; Su SG; Zheng YL; Yang X; Jiang N; Fu L; Zhou J; Zhang Y; Deng R; Wang CH; Lu SX; Huang YH; Liu LL; Zhang C; Yun JP
Cancer Lett; 2022 Feb; 526():236-247. PubMed ID: 34767927
[TBL] [Abstract] [Full Text] [Related]
7. miR‑300 regulates tumor proliferation and metastasis by targeting lymphoid enhancer‑binding factor 1 in hepatocellular carcinoma.
Chen Y; Guo Y; Li Y; Yang J; Liu J; Wu Q; Wang R
Int J Oncol; 2019 Apr; 54(4):1282-1294. PubMed ID: 30968150
[TBL] [Abstract] [Full Text] [Related]
8. Lymphoid enhancer-binding factor-1 promotes stemness and poor differentiation of hepatocellular carcinoma by directly activating the NOTCH pathway.
Fang S; Liu M; Li L; Zhang FF; Li Y; Yan Q; Cui YZ; Zhu YH; Yuan YF; Guan XY
Oncogene; 2019 May; 38(21):4061-4074. PubMed ID: 30696957
[TBL] [Abstract] [Full Text] [Related]
9. Fucosyltransferase 8 as a functional regulator of nonsmall cell lung cancer.
Chen CY; Jan YH; Juan YH; Yang CJ; Huang MS; Yu CJ; Yang PC; Hsiao M; Hsu TL; Wong CH
Proc Natl Acad Sci U S A; 2013 Jan; 110(2):630-5. PubMed ID: 23267084
[TBL] [Abstract] [Full Text] [Related]
